UCLA

Chem 218: Student Exit Seminar
2022-03-10 12:00 (America/Los_Angeles)
“Choosing the right lens: Energy surfaces and chemical identity in the photodissociation of Na2+ in different solvent environments”

Special Organic Colloquium - Prof. Herman O. Sintim
2022-03-10 16:00
Novel chemotypes of kinase inhibitors for the potential treatment of recurrent cancers
Abstract: Therapeutic resistance remains a critical issue in cancer treatment. While cancer patients who harbor dysregulated protein kinases benefit from the use of kinase inhibitors (KIs), many fail therapy and almost all patients become resistant to treatment, indicating a critical unmet need to prevent treatment failure.
Thus far (as of December 2021), the FDA has approved 69 protein kinase inhibitors and several others are also in various stages of clinical trials. Although many compounds that inhibit protein kinases have been described in the literature, only a small region of the chemical space has been explored for protein kinase inhibition and the majority of FDA approved kinase inhibitors contain only a handful of core moieties, such as indazole, quinoline, isoquinoline, quinazoline, pyrazole and pyrimidine. To belabor this point, about ~20% of FDA-approved protein kinases contain the pyrimidine moiety while six drugs contain quinazoline and eight drugs contain pyrazole. In other words, about 50% of approved protein kinase inhibitors contain one of pyrimidine, pyrazole or quinazoline, highlighting the lack of progress in using other regions of the chemical space to drug protein kinases. The Sintim group, integrating computational and experimental workflows, has identified a few novel chemotypes that inhibit disease-associated protein kinases (such as FLT3, RET, CDKs, Haspin) with sub-nanomolar IC50 values. Some of these new KI are long residence time (hours) inhibitors and have shown impressive efficacies in animal models of various cancers. Two of such compounds are currently undergoing toxicology studies to determine safe dosing regimens for potential phase 1 clinical trials against drug-resistant FLT3 (F691L and D835V/Y)-driven AML and RET (solvent front mutations)-driven lung cancers

Chem 268 - John E. (Jack) Johnson
2022-03-11 15:30
“Biophysical Studies of an RNA Virus particle and its Maturation: Insights into an Elegantly Programmed Nano-machine”

NSF Center for Integrated Catalysis Webinar Series
2022-03-15 12:30
“Towards understanding the role of mass transport in electrocatalysis: the role of dimensionless analysis and multi-scale modeling”

Catalysis Lectureship 2022 - Christophe Copéret, ETH Zürich
2022-03-16 14:30
Bridging the gap between well-defined and industrial catalysts via a molecular approach
Industrial processes, in particular large-scale ones, mostly rely on heterogeneous catalysts. The search for more sustainable processes and the changes in environmental policies impose the continuous development of improved catalyst performances and catalytic processes, as well as the exploration of alternative routes. However, due to their inherent complexity, heterogeneous catalysts are mostly developed empirically rather than through detailed structure – activity relationships as the nature of the active sites are rarely known.
In this context, our group has been interested in understanding and controlling chemistry on surfaces, with the ultimate goal to generate isolated metal sites with defined chemical environment.[1] This approach has been used to develop highly active and selective single-site catalysts that can overperformed their homogeneous counterparts, but it can also provide useful information to understand and further develop industrial catalysts[2] or to study much more complex systems such as supported nanoparticles, where support effects, interfaces, alloying… remain complex to understand at the molecular level.
This lecture will be developed around these themes and will show that a careful characterization of surface sites on a molecular level is key to develop high performance catalysts and to bridge the gap between fundamental and applied catalysis.[3]
References:
1 C. Copéret, A. Comas-Vives, M. P. Conley, D. Estes, A. Fedorov, V. Mougel, H. Nagae, F. Núñez-Zarur, P. A. Zhizhko Surface Organometallic and Coordination Chemistry towards Single-Site Heterogeneous Catalysts: Strategies, Methods, Structures, and Activities. Chem. Rev. 2016, 16, 323-421. DOI: 10.1021/acs.chemrev.5b00373
2 C. Copéret, F. Allouche, K. W. Chan, M. P. Conley, M. F. Delley, A. Fedorov, I. B. Moroz, V. Mougel, M. Pucino, K. Searles, K. Yamamoto, P. A. Zhizhko, Bridging the Gap between Industrial and Well-Defined Supported Catalysts. Angew. Chem. Int. Ed. 2018, 57, 6398-6440. DOI: 10.1002/anie.201702387
3 a) C. Copéret Single-Sites and Nanoparticles at Tailored Interfaces Prepared via Surface Organometallic Chemistry from Thermolytic Molecular Precursors. Acc. Chem. Res. 2019, 52, 1697-1708. DOI: 10.1021/acs.accounts.9b001388. b) Deciphering Metal-Oxide and Metal-Metal Interplay via Surface Organometallic Chemistry: A Case Study with CO2 Hydrogenation to Methanol. S. R. Docherty, C. Copéret J. Am. Chem. Soc. 2021, 143, 6767–6780. DOI: 10.1021/jacs.1c02555. c) Heterogeneous Alkane Dehydrogenation Catalysts Investigated via a Surface Organometallic Chemistry Approach. S. R. Docherty, L. Rochlitz, P.-A. Payard, C. Copéret Chem. Soc. Rev. 2021, 50, 5806 – 5822. DOI: 10.1039/d0cs01424a.

Chem 278: Prof. Kimberly A. See
2022-03-16 16:15
“One is the Loneliest Number: Multivalent and Multielectron Processes for Next-Generation Batteries”

Chem 218 Student Exit Seminar: Yiyi Yao
2022-03-17 12:00
“Structural Stability and Phase Transformation Behavior in Nanostructured Energy Storage Materials”

Special Organic Colloquium - Prof. Joshua G. Pierce
2022-03-24 16:00
Complex Molecule Synthesis at the Interface of Biology: Adventures in Medicinal Chemistry and Chemical Biology

Chem 228: Prof. Thuc-Quyen Nguyen
2022-03-28 16:00
“Understanding Unconventional Doping Mechanisms in Organic Semiconductors”

Chem 278: Prof. Karsten Meyer
2022-03-29 16:00
“Super-Oxidized” Iron Nitrido/Imido and “Super-Reduced” Iron Nitrosyl Complexes in tris-Carbene Coordination Spheres – and how Iron Really Feels About it

The 2022 Cabot Microelectronics Corp. Lecture
2022-03-30 16:00
A new era in solar energy conversion and optoelectronics enabled by the humble halide perovskites?

Chem 218 Student Exit Seminar: Gail Vinnacombe
2022-03-31 12:00
“Surface Functionalization, Patterning, and in Situ Growth of Gold Nanoparticles”

Organic Colloquium - Prof. Vincent N. G. Lindsay
2022-03-31 16:00
Stereoselective Synthesis and Applications of Sulfonylcyclopropanols as Modular Cyclopropanone and Homoenolate Equivalents

Chem 268 (Midstream Presentation) - Alexander Stevens
2022-04-01 15:30

Chem 228: Prof. Dan Neumark
2022-04-04 16:00
“Attosecond Science and its Applications to Atomic, Molecular, and Chemical Physics”

Chem 263 Student Exit Seminar- Christopher Sue
2022-04-05 16:00

Chem 278: Prof. Robert J. Gilliard
2022-04-06 16:00
“Beryllium, Boron, and Bismuth: From Fundamental Redox Chemistry to Luminescent Materials”

No Seminar
2022-04-07 16:00, 2022-04-14 16:00

Chem 268 (Midstream Presentation) - Noelle Novales and Sean Atamdede
2022-04-08 15:30

NSF Center for Integrated Catalysis Webinar Series
2022-04-12 12:30
Stereoconvergent and Stereodivergent Synthesis with Configurationally Unstable Compounds

Chem 263/Chemical Biology Seminar-Professor Jeremy Baskin
2022-04-12 16:00
Questions? Please contact Isabella Diaz at maynardadmin@chem.ucla.edu

Chem 278: Prof. Alina M. Schimpf
2022-04-13 16:00
“Solution-phase routes to inorganic solid-state materials”

Chem 268 (Midstream Presentation) - Andrew Goring and Ashley Julio
2022-04-15 15:30

Chem 228: Prof. Shu-ou Shan
2022-04-18 16:00
“Nascent Protein Selection and Triage at the Ribosome”

Chem 263/Chemical Biology Seminar-Prof. Pamela Chang
2022-04-19 16:00

Chem 278: Prof. Adam S. Veige
2022-04-20 16:00
TBA

Chem 218 Student Exit Seminar - Chris Dunham
2022-04-21 12:00

Organic Colloquium - Prof. Andrew McNally
2022-04-21 16:00
Selective Functionalization of Pyridines, Diazines and Pharmaceuticals via Unconventional Intermediates

Chem 268 - Naomi Courtemanche
2022-04-22 15:30
“Actin filament assembly mediated by formins: All roads lead to the barbed end”
Normal
0
false
false
false
EN-US
X-NONE
X-NONE

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin-top:0in;
mso-para-margin-right:0in;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0in;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:”Calibri”,sans-serif;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:”Times New Roman”;
mso-bidi-theme-font:minor-bidi;}
